18 June 2007

Pronota strengthens commercial team with appointment of Business Development Director

Ghent, Belgium; 18 June 2007 - Pronota nv, the Belgium-based predictive biomarker company, has announced the appointment of Dr Huw Davies as Business Development Director, with immediate effect. This is a new position created within Pronota and reflects the Company’s commercial focus as it brings its protein biomarker discovery services to the market.

With more than a decade of commercial experience in the Life Sciences sector, Dr Davies comes to Pronota from Ciphergen Biosystems in Guildford, UK, where he was Program Manager for the UK, Ireland and The Netherlands. Dr Davies was also Manager of the European Biomarker Discovery Centre, liaising with pharmaceutical clients and clinical collaborators and leading to the development and characterisation of novel biomarkers. Dr Davies holds a PhD from the John Innes Centre, Norwich, UK, and a first class degree in biological sciences.

Commenting on the new appointment, Nick McCooke, chief executive officer of Pronota, said: "I am extremely pleased to welcome Huw to the Pronota team. Huw brings considerable experience in business development and the commercialisation of biomarker discovery platforms in the life science sector. He also has experience in managing biomarker discovery programs and this expertise will be of value as Pronota continues to move forward with developing its own protein-based diagnostic and pharmacodiagnostic products".

Dr Davies commented: "I am very pleased to join the Pronota team. I have been very impressed with the capabilities of Pronota’s technology, particularly its ability to reproducibly identify and measure biomarkers of low abundance in blood. This will be of immense value in the discovery of biomarkers both in a service offering to pharma and in the company’s own programs for developing diagnostics and pharmacodiagnostics".

- ENDS -

Notes to editors:

About Peakadilly (Pronota)

Peakadilly, which changed its name to Pronota in November 2006, was founded in late 2004 to exploit the protein biomarker discovery technology developed at VIB and the University of Ghent. In this short time, it has successfully implemented the technology and won revenue generating projects with big pharma. It applies the technology both to third party projects and to its own projects for developing a new generation of diagnostics and pharmacodiagnostic products.

http://www.pronota.com